Watch for regulatory submission timelines and potential FDA breakthrough therapy designation. The 51% HR reduction is clinically meaningful and could support accelerated approval. Monitor upcoming medical meeting presentations for full data.
Price Chart
Executive Summary
Genmab and AbbVie announced positive topline Phase 3 results for epcoritamab + R-CHOP in newly diagnosed DLBCL, showing a 51% reduction in risk of disease progression or death (HR 0.49, p=0.0001). This is the first Phase 3 bispecific antibody combination to demonstrate statistically significant PFS improvement in frontline DLBCL. Genmab and AbbVie will engage global regulatory authorities for potential approval.
Key Facts
- Phase 3 EPCORE DLBCL-2 trial met primary endpoint: PFS improvement in newly diagnosed DLBCL patients with IPI score 2-5
- Risk of disease progression or death reduced by 51% (HR 0.49; 95% CI 0.36-0.67; p=0.0001) for primary endpoint population (IPI 3-5)
- First Phase 3 study of a bispecific antibody combination to show statistically significant PFS benefit in frontline DLBCL
- Safety profile consistent with known profiles of epcoritamab and R-CHOP individually
- Genmab and AbbVie will engage global regulatory authorities for next steps
Financial Impact
Potential label expansion for epcoritamab into frontline DLBCL, a market with ~25,000 new U.S. cases annually. No financial figures provided in filing.
Risk Factors
- Regulatory approval not guaranteed; combination is investigational and not yet approved
- Competition from other frontline DLBCL therapies including CAR-T and other bispecifics
- Long-term safety and durability data still maturing
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001434265-26-000132 |
| Document: gmab_20261005x6k.htm | 0001434265-26-000132 |
| Document: 0001434265-26-000132-index-headers.html | 0001434265-26-000132 |
| Document: 0001434265-26-000132-index.html | 0001434265-26-000132 |
| Document: 0001434265-26-000132.txt | 0001434265-26-000132 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | 6-K | $42.64 | awaiting T+1 | — | $43.79 (+2.70%) |
Oct 13, 2026 13d ago | 6-K | $36.57 $36.89 | ▲ +0.88% | ▲ +1.96% | $43.79 (+19.74%) |
Oct 7, 2026 18d ago | 6-K | $36.65 $36.05 | ▼ −1.64% | ▼ −1.21% | $43.79 (+19.48%) |
Oct 5, 2026 20d ago | SC 13G | $37.80 $36.65 | ▼ −3.04% | ▼ −2.80% | $43.79 (+15.85%) |
Oct 5, 2026 20d ago | 6-K | $38.48 $37.80 | ▼ −1.77% | ▼ −2.32% | $43.79 (+13.80%) |
Oct 2, 2026 23d ago | 6-K | $34.75 $38.48 | ▲ +10.73% | ▲ +10.06% | $43.79 (+26.01%) |
Sep 29, 2026 26d ago | 6-K | $35.57 $35.68 | ▲ +0.30% | ▲ +0.50% | $43.79 (+23.11%) |
Sep 24, 2026 4w ago | 6-K | $34.83 $35.32 | ▲ +1.41% | ▲ +0.86% | $43.79 (+25.72%) |
Sep 8, 2026 6w ago | 6-K | $33.53 $33.04 | ▼ −1.46% | ▼ −1.00% | $43.79 (+30.60%) |
Aug 12, 2026 10w ago | 6-K | $31.42 $31.34 | ▼ −0.25% | ▼ −0.95% | $43.79 (+39.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers